Pfizer announces positive results from Phase 3 Study of Abrysvo
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
The preventive and promotive approach of our traditional health care systems has played a significant role in modern age today
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
Subscribe To Our Newsletter & Stay Updated